Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. She exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, converting options into shares.
On the same date, she sold 9,500 common shares in a series of open-market trades at prices ranging from $528.51 to $537.37 per share, leaving 40,513 shares held directly. The filing also lists additional indirect holdings through her spouse and several family trusts. All transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027 or December 31, 2026.
UNITED THERAPEUTICS Corp President and COO Michael Benkowitz reported routine equity compensation activity involving restricted stock units and common shares. On March 15, 2026, a trust associated with him exercised restricted stock units that each convert into one share of common stock, resulting in 33,382 shares of common stock held indirectly by the trust.
Of these shares, 14,706 shares of common stock were withheld by United Therapeutics to satisfy tax obligations upon vesting, a non-market disposition that does not represent an open-market sale. Following these transactions, the filing shows 19,046 shares held indirectly by the trust and 2,710 shares held directly, which includes 62 shares acquired earlier under the company’s employee stock purchase plan.
United Therapeutics Corp CFO and Treasurer James Edgemond exercised restricted stock units into 19,478 shares of common stock on March 15, 2026. These awards converted one-for-one into common shares following vesting, reflecting performance-based and time-based equity compensation.
To cover tax obligations at vesting, 8,786 shares were withheld by United Therapeutics at a price of $536.12 per share. These F-code transactions are tax-withholding dispositions, not open-market sales. After all transactions, Edgemond directly holds 18,876 shares of common stock, including 42 shares acquired under the employee stock purchase plan.
United Therapeutics EVP & General Counsel Paul A. Mahon reported the vesting and conversion of restricted stock units into common shares. On March 15, 2026, 16,691 restricted stock units converted on a one-for-one basis into 16,691 shares of common stock, reflecting time- and performance-based awards granted in March 2023.
To cover tax obligations upon vesting, 8,363 of these shares were withheld by United Therapeutics at a reference price of $536.12 per share, rather than sold in the open market. After these transactions, Mahon directly owns 45,172 shares of United Therapeutics common stock.
United Therapeutics Chairperson and CEO Martine A. Rothblatt reported vesting and settlement of restricted stock units rather than open-market trades. On March 15, 2026, she exercised and converted a total of 69,579 restricted stock units into the same number of common shares on a one-for-one basis.
To cover tax obligations associated with these vestings, 29,196 common shares were withheld by United Therapeutics at $536.12 per share, a non-market tax-withholding disposition. After these transactions, Rothblatt directly held 40,513 shares of common stock, and the filing also shows additional indirect holdings through her spouse and various family trusts.
United Therapeutics director Jan Malcolm reported an open-market sale of company stock. On March 17, 2026, Malcolm sold 45 shares of Common Stock at an average price of $533.51 per share, and now directly holds 125 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Malcolm entered into on September 11, 2025, indicating the transaction was scheduled in advance rather than timed discretionarily.
UTHR files a Form 144 reporting the proposed sale of 45 shares of Common Stock (restricted stock) by an issuer-affiliated holder.
The filing lists multiple recent dispositions by the same holder: 50 shares sold on 03/03/2026 for $25,460.00, and prior 50-share sales on 02/17/2026, 02/03/2026, 01/20/2026, 01/06/2026, and 12/23/2025 with reported gross proceeds shown for each sale. The transactions are reported under Rule 144 notice requirements.
UTHR filed Form 144 reporting sale transactions by Judy Olian. The filing lists two sales of Common shares: 03/02/2026 (200 shares, $101,910.00) and 03/09/2026 (200 shares, $102,000.00). The securities are listed as Restricted Stock with an original grant date of 06/26/2021.
UNITED THERAPEUTICS Corp director Judy D. Olian reported an open-market sale of company stock. On March 16, 2026, she sold 200 shares of Common Stock at an average price of $535.44 per share in a sale classified as an open-market transaction.
After this sale, she directly holds 4,445 shares of UNITED THERAPEUTICS Common Stock. According to a footnote, this transaction was executed under a pre-arranged Rule 10b5-1 trading plan that she entered into on November 24, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share and on the same date sold 9,500 shares in open-market trades at weighted average prices between $535.43 and $542.04. The filing states these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. After the transactions, she holds 7,150 shares directly and additional indirect holdings through her spouse and family trusts totaling several hundred thousand shares.